In OS, sorafenib inhibits proliferation of tumour growth, angiogenesis (VEGF), invasion (MMP2), and the emergence of pulmonary metastases (Erzin/β4-intégrin/PI3K) and induces apoptosis [47]. Here, MMP2 is linked to neoplasm.